ACADIA is lowering its 2018 NUPLAZID net sales guidance to be between $210 million and $225 million from a previous range of $255 million to $270 million. For the third quarter of 2018, ACADIA expects NUPLAZID net sales to be between $52 million and $59 million. ACADIA is lowering its guidance for its year end 2018 cash, cash equivalents and investment securities on its balance sheet to be between $155 million to $170 million from previous guidance of over $200 million. This updated guidance is inclusive of the $10 million upfront fee and initial research and development expenses for trofinetide.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.